1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Oppositional Defiant Disorder (ODD) Global Clinical Trials Review, H2, 2016

Oppositional Defiant Disorder (ODD) Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Oppositional Defiant Disorder (ODD) Global Clinical Trials Review, H2, 2016" provides an overview of Oppositional Defiant Disorder (ODD) clinical trials scenario. This report provides top line data relating to the clinical trials on Oppositional Defiant Disorder (ODD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Oppositional Defiant Disorder (ODD) Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2


Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 7
Top Five Countries Contributing to Clinical Trials in Europe 8
Top Countries Contributing to Clinical Trials in North America 9
Clinical Trials by G7 Countries: Proportion of Oppositional Defiant Disorder (ODD) to Central Nervous System Clinical Trials 10
Clinical Trials by Phase in G7 Countries 11
Clinical Trials by Phase 12
Clinical Trials by Trial Status 13
Clinical Trials by End Point Status 14
Subjects Recruited Over a Period of Time 15
Clinical Trials by Sponsor Type 16
Prominent Sponsors 17
Top Companies Participating in Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials 18
Clinical Trial Profile Snapshots 19
Appendix 28
Abbreviations 28
Definitions 28
Research Methodology 29
Secondary Research 29
About GlobalData 30
Contact Us 30
Disclaimer 30
Source 31

List of Tables
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials by Region, 2016* 5
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 7
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 8
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, North America, Top Countries, 2016* 9
Proportion of Oppositional Defiant Disorder (ODD) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 10
Oppositional Defiant Disorder (ODD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 11
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials by Phase, 2016* 12
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 13
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 14
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 15
Oppositional Defiant Disorder (ODD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 16
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 17
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 18

List of Figures
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 7
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 8
Proportion of Oppositional Defiant Disorder (ODD) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 10
Oppositional Defiant Disorder (ODD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 11
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 12
Oppositional Defiant Disorder (ODD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 13
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 15
Oppositional Defiant Disorder (ODD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 16
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 17
Oppositional Defiant Disorder (ODD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 18
GlobalData Methodology 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bipolar disorder (BPD)  - Market Insights, Epidemiology and Market Forecast-2023

Bipolar disorder (BPD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Bipolar disorder (BPD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Bipolar disorder (BPD) fo ...

Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Bipolar disorder (BPD)  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Bipolar disorder (BPD)  in seven major markets (US, France, Germany, Italy, ...

Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.